Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities
Net income (loss) - before noncontrolling interest (“NCI”)	$ 60,711	$ (21,750)	$ 27,285	$ (61,855)
Adjustments to reconcile net income (loss) - before NCI to net cash used in operating activities
Depreciation and amortization expense			1,129	2,207
Stock-based compensation	1,931	2,245	5,716	9,171
Gain on sale of intellectual property				(1,000)
Gain on deconsolidation of subsidiary	(72,287)		(72,287)
Change in fair value - equity method investment	(407)		(407)
APA-RDx: Issue common stock of subsidiary - termination payment				713
Amortization of common stock payment for vendor service agreement			448	625
Change in fair value - Senior Secured Convertible Notes	(240)	4,392	2,488	5,772
Loss on issue - Senior Secured Convertible Note				1,111
Debt extinguishment loss - Senior Secured Convertible Note	1,403	1,764	2,535	3,032
Change in fair value - derivative liability				291
Non-cash lease expense			8	304
Changes in operating assets and liabilities:
Accounts receivable			45	(18)
Prepaid expenses, deposits and current and other assets			579	(1,757)
Accounts payable			(249)	(538)
Accrued expenses and other current liabilities			(938)	1,780
Net cash flows used in operating activities			(33,648)	(40,162)
Cash flows from investing activities
Purchase of equipment			(51)	(59)
Decrease in cash due to deconsolidation of subsidiary			(16,479)
Proceeds from sale of intellectual property to Lucid Diagnostics Inc.			350
Proceeds from sale of intellectual property				1,000
Net cash flows provided by (used in) investing activities			(16,180)	941
Cash flows from financing activities
Proceeds – issue of preferred stock - subsidiary			29,798	13,625
Proceeds – issue of Senior Secured Convertible Note				10,000
Payment – Senior Secured Convertible Note – acceleration floor payments			(531)
Proceeds – issue of common stock - At-The-Market Facility			1,268	1,166
Proceeds – subsidiary common stock - Committed Equity Facility and At-The-Market Facility				284
Proceeds – issue common stock – Employee Stock Purchase Plan			62	259
Proceeds – subsidiary common stock – Employee Stock Purchase Plan			353	551
Proceeds – exercise of stock options issued under equity plan of subsidiary			4
Net cash flows provided by financing activities			30,954	25,885
Net increase (decrease) in cash			(18,874)	(13,336)
Cash, beginning of period			19,639	39,744
Cash, end of period	$ 765	$ 26,408	$ 765	$ 26,408